science wire

Secukinumab (AIN457) patients' skin cleared faster and for longer than Enbrel (etanercept) patients, beginning as early as Week 2 Study also showed twice as many secukinumab patients experienced clear or almost clear skin by Week 12 versus Enbrel Head-to-head study of secukinumab and Enbrel part of largest clinical program completed in moderate-to-severe plaque psoriasis with more than 3,300 patients Secukinumab is the first IL-17A inhibitor wit

Real-world data showed Gilenya reduced the annualized relapse rate and risk of relapse by around 50% versus interferons or glatiramer acetate Reducing the frequency and probability of future relapses in patients with MS is a key treatment goal, as relapses can significantly advance an individual's level of disability Recovering from a relapse can take weeks or months for a patient with MS, and approximately half of all relapses may leave lasting

FDA grants Roche's Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer The Perjeta regimen is the first treatment approved under a new FDA pathw

Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel * (etanercept) in moderate-to-severe plaque psoriasis to be revealed Results from three additional secukinumab Phase III studies also to be presented for the first time Secukinumab is the first IL-17A inhibitor with Phase III data and is on track to be the first psoriasis medication filed targeting IL-17A New data to be reported from final omalizumab registra

Pivotal myopic CNV trials with Lucentis (ranibizumab) show visual acuity improvement of nearly 14 letters with a median of two injections at one year New data suggest early treatment initiation with Lucentis results in better vision gains in DME patients Meta-analysis of 14 trials and 6504 patients confirms well-established Lucentis safety profile reported from real-world experience and extensive clinical trials Basel, September 27, 2013 - New c

New four-year data will show continued Gilenya treatment reduced brain volume loss in MS patients compared to delaying treatment with Gilenya by two years Data will strengthen the link between brain volume loss and disability progression, highlighting the importance of reducing brain volume loss in patients with MS Real-world patient data will confirm superiority of Gilenya compared to standard therapies (interferon and glatiramer acetate) in re

Ultibro Breezhaler (QVA149) is the first once-daily dual bronchodilator to gain European Commission approval as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD In Japan, once-daily Ultibro Inhalation Capsules (QVA149), delivered through the Breezhaler device, approved for relief of various symptoms due to airway obstruction in COPD Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including breathlessness and rescue medication use, compared to current standards of care - .

Power of One enables the public to fund malaria tests and treatments for children in Africa through the latest online and mobile technology Novartis is the exclusive campaign treatment sponsor and wi

CML community recognizes September 22 as World CML Day to raise awareness of the needs of patients living with CML Novartis commemorates World CML Day, announcing 100+ study sites across 40 countries now enrolling patients to its global treatment-free remission clinical trials Treatment-free remission program evaluates whether patients can maintain undetectable levels of disease after stopping nilotinib therapy Basel, September 19, 2013 - Novart

New analyses in the IGNITE clinical trial program showed that QVA149 provided superior, rapid and sustained improvements in lung function and significantly reduced shortness of breath versus comparator therapies , BLAZE study also demonstrated significant improvements in shortness of breath with QVA149 compared to tiotropium 18 mcg in patients with moderate-to-severe COPD SPARK study showed similar rates of reduction in exacerbations with once-d

Research collaboration advances company goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need Strategic research collaboration enlarges scop

Novartis reaffirms continued innovation in transplant during anniversary year of breakthrough therapy, ciclosporin TRANSFORM trial to be presented : largest ever study of its kind, evaluating Certica

Robust efficacy of once-daily Ultibro Breezhaler (QVA149) supported by a pooled analysis of the Phase III IGNITE clinical trial program further strengthens evidence for the Ultibro LABA+LAMA combination for the treatment of COPD patients , , Once-daily Seebri Breezhaler (glycopyrronium) efficacy data strengthened by new analyses from the SPARK study on exacerbations and lung function in severe and very severe COPD patients , Basel, September 4,

Ilaris is the first interleukin-1 beta (IL-1 beta) inhibitor for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) and is the only treatment approved specifically for SJIA that is given

New analysis of RELAX-AHF published in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress , If approved, RLX030 has the potential to be the first treatment breakthrough for AHF patients in 20 years , Basel, September 2, 2013 - Results from a new analysis of the Phase III RELAX-AHF study published today in the European Heart Journal and presented as a late breaker at the European Society of C

BYM338 is the third Novartis investigational treatment this year to receive a breakthrough therapy designation by the FDA, highlighting Novartis' leadership in the industry in breakthrough therapy designations Basel, August 20, 2013 - Novartis announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM).

Australia approval marks a key step in expanding access to the first and only broad coverage vaccine against MenB disease , ; Bexsero was granted European licensure this past January MenB disease is

The non-profit CEO Roundtable on Cancer has recognized the programs Novartis has to support associates in the prevention, diagnosis and treatment of cancer Originally recognized for these efforts in

Everolimus did not show survival benefit for patients with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafinib Study results do not impact use of Afinitor in othe

Meningococcal disease is a leading cause of bacterial meningitis, a rapidly progressing disease that can lead to death in otherwise healthy children , The highest rates of meningococcal disease in th

The CHMP has endorsed the use of Ilaris in patients aged 2 years and older who suffer from Systemic Juvenile Idiopathic Arthritis (SJIA) In Phase III studies, 84% of Ilaris-treated SJIA patients achi

QVA149 (indacaterol/glycopyrronium) is the first once-daily fixed-dose combination of both a LABA and a LAMA bronchodilator to gain positive CHMP opinion Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including breathlessness and rescue medication use, compared to current standard of care QVA149 demonstrated significantly reduced rates of COPD exacerbations and improved health-relat

JCVI takes interim position to not recommend Bexsero for the routine immunization program, driven by evaluation based on cost-effectiveness assumptions The evaluation by JCVI was made prior to any pr

Scientists at EPFL have developed a quick and simple method for connecting and assembling new molecules together, paving a new road for synthetic chemistry, material science, chemical biology, and even drug discovery. Thiols are sulfur-containing molecules found in most proteins of the human body. Characterized by their 'garlicky' smell, they also give coffee, sweat and the spray of skunks their unique odor.

Under the leadership of Nancy Hynes, scientists from the Friedrich Miescher Institute for Biomedical Research have identified a potential novel target for breast cancer treatment. The scientists could show that breast cancer patients with high levels of the receptor tyrosine kinase Ret have a worse prognosis; and that blocking Ret not only decreases tumor growth but also impacts the potential of the cancer to spread throughout the body.

Group net sales increased 1% (+3% cc ) versus year ago to USD 14.5 billion in second quarter, up 2% (+4% cc) to USD 28.5 billion in first half Core operating income was USD 3.8 b

License agreement advances a Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions More than 21 million cases of typhoid fever and five millio

FIXTURE trial of more than 1,300 moderate-to-severe plaque psoriasis patients showed superiority of secukinumab (AIN457) to Enbrel (etanercept) FIXTURE is a pivotal trial for registration; Regulatory submissions for secukinumab (AIN457), a therapy targeting IL-17A, are on tr ack for the second half of 2013 Basel, July 8, 2013 - Novartis announced today top-line results from the head-to-head Phase III psoriasis study which showed the superiority of secukinumab (AIN457) in clearing skin to Enbrel * (etanercept), an anti-tumor necrosis factor (anti-TNF) therapy.

Lucentis (ranibizumab) is the first licensed therapy to improve vision in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Pivotal trial shows average visual acuity improvement of up to 14 letters at one year with a median of only two injections with Lucentis treatment Myopic CNV, the growth of abnormal leaky blood vessels in the back of the eye in high myopia, often causes irreversible deteriora

Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU) Omalizumab found to be effective, safe and well tolerated in refractory CSU patients, including those on antihistamines at up to four times the approved dose By Week 12 omalizumab eliminated or suppressed symptoms in more than half of patients who failed multiple therapies; benefit sustained during active tr

Holzkirchen, Germany, June 24, 2013 - Sandoz, the global leader in biosimilars, announced it has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen's Enbrel ).

Recognition by the US Food and Drug Administration (FDA) that RLX030 has the potential to address a serious unmet medical need If approved, RLX030 has the potential to be the first treatment breakthrough for Acute Heart Failure patients in 20 years[1,2] RLX030 is the second Breakthrough Therapy designation by the FDA for Novartis investigational treatments, following LDK378 Basel, June 21 , 2013 - Novartis announced today that the US Food and Dr

Jakavi reduced risk of death by 52% and sustained reductions in spleen size in new three-year COMFORT-II study data Analysis from a separate trial suggested that long-term treatment with Jakavi may stabilize or improve bone marrow fibrosis, a key marker of worsening disease Basel, June 16, 2013 - Novartis today announced results from a Phase III three-year follow-up study that showed Jakavi (ruxolitinib) demonstrated improved overall survival and sustained reductions in spleen size compared to conventional therapy.

Gilenya resulted in almost 50% more patients being free of MS disease activity after the switch from standard interferon treatment Annualized relapse rate reduced by >50% after 1 year for patients who switched from standard interferon treatment to Gilenya Reduced rate of brain volume loss sustained for up to 4.5 years in patients with active disease, despite prior treatment, who switched from interferon to Gilenya Basel, June 10 , 2013

Gilenya improved the key measures: brain volume loss, MRI lesion activity, relapse rates and disability progression Switching to Gilenya from interferon increased the proportion of patients disease free after one year of treatment Gilenya resulted in sustained reduction of annualized relapse rate and the rate of brain volume loss in patients switched from interferon treatment Basel, June 5 , 2013 - New data will be presented at the 23 rd meeting

Investigational compound LDK378 is a selective inhibitor of ALK , a target found in metastatic non-small cell lung cancer (NSCLC) Data show 60% overall response rate in 78 patients with ALK+ NSCLC taking LDK378 at 750 mg; will serve as basis for first filing in early 2014 FDA designated LDK378 as Breakthrough Therapy in March and a robust clinical development plan is underway Basel, June 3 , 2013 - Novartis today announced data on its investigat

A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients First Phase III study sho

Lucentis recommended for approval in EU to treat patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Lucentis superior to current standard of care and i

Latest Phase III research on Afinitor in HER2 positive advanced breast cancer Jakavi TM overall survival advantage evaluated in three-year study in patients with myelofibrosis, a rare and life-threat

New campaign 'MS and:Our Story' announced today, providing MS community with platform to share experiences of life with MS Launch of new Novartis social media platforms to help generate dialogue, inf

INTERVAL study marks first assessment of the feasibility of setting and achieving individualized goals in this difficult-to-treat population of type 2 diabetes patients Study shows elderly type 2 diabetes patients three times more likely to reach an individualized HbA1c goal with no tolerability issues with vildagliptin than placebo Previous studies raised questions of uniform HbA1c targets for elderly type 2 diabetes patients, but no trials of

BLAZE study showed once-daily QVA149 significantly improved patient self-reported shortness of breath and lung function compared to placebo and tiotropium 18 mc g SPARK results showed that QVA149 significantly reduced rate of all exacerbations compared to glycopyrronium 50 mcg and open-label tiotropium 18 mcg , Pooled GLOW 1 and 2 data showed once-daily Seebri Breezhaler (glycopyrronium) significantly improved lung function in the first 4 hours

Breast cancer is the most common cancer in women worldwide, yet survey confirms many women living with advanced form of disease feel isolated , Three in four women surveyed say they actively seek out

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Everolimus plus trastuzumab and vinorel

Ilaris (canakinumab) is the first interleukin-1 beta inhibitor for the treatment of SJIA and the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection In Pha

UK real world study shows 59% reduction of legal blindness attributable to wet AMD since introduction of Lucentis with 9.7 injections spread over 5 years New one year REPAIR data shows visual acuity improvement of 14 letters with an average of 3.

CHMP recommends conditional EU approval of Roche's Erivedge for advanced basal cell carcinoma, a rare but potentially devastating form of skin cancer Roche announced today that the European Union's C